Special population use of Infiglatinib in Laos' Lucius version
The use of Infiglatinib in special populations needs to be adjusted based on pregnancy, lactation, liver and kidney function, and strict risk assessment and individualized measures should be taken. The following classification explains key precautions and dosage adjustment principles.
1. Medication during pregnancy
(1) Animal studies have shown that it may cause fetal malformations, and pregnant women should avoid using it. Before treatment, it is necessary to confirm the pregnancy status and strictly use contraception during medication.
(2) If accidentally exposed during pregnancy, the risk to the fetus should be evaluated immediately and treatment should be terminated.
2. Medication during lactation
(1) It is not yet clear whether the medication enters breast milk, but the potential risk is high. Breastfeeding is prohibited during the treatment period and within one week after the last dose.
(2) During lactation, it is necessary to weigh the pros and cons and suspend breastfeeding if necessary.
3. People with reproductive potential
(1) Female patients need to take effective contraceptive measures during treatment and one month after discontinuing medication.
(2) Male patients should use barrier contraception during treatment and one week after discontinuing medication to avoid drug transmission through semen.
4. Children's medication
(1) The safety and efficacy of bile duct cancer patients aged 12 and above are partially supported by data, and strict monitoring of growth indicators is necessary.
(2) Children under 12 years old without clear medication basis are prohibited from use.
5. Elderly medication
(1) Patients over 65 years old do not need to adjust the dosage, but it is necessary to strengthen the monitoring of adverse reactions.
(2) Data for patients over 80 years old is limited, it is recommended to reduce usage by 20%.
6. Liver dysfunction
(1) Reduce the dosage to 80mg/day for Child Pugh Class A patients and 60mg/day for Class B.
(2) Child Pugh Class C is prohibited and an alternative solution is required.
7. Renal insufficiency
(1) Mild to moderate damage (eGFR30-89mL/min) does not require dose adjustment.
(2) Severe damage (eGFR<30mL/min) or lack of data in dialysis patients, it is recommended to avoid use.
Disclaimer：《Special population use of Infiglatinib in Laos' Lucius version》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！